GlassScriptPhysician profile
Michelle Petro
NPI 1679561948
$1,638.96
in general payments reported to CMS, 2019-2025
23 companies · $312 in 2025
The $312 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $199 · 2021: $275 · 2022: $221 · 2023: $306 · 2024: $208 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $826.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $402.02 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $375.52 | 2019-2023 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $205.91 | 2020-2025 | Entyvio, Gattex |
| Celgene Corporation | $132.32 | 2021-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $102.58 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $92.90 | 2020-2024 | Linzess |
| Ipsen Biopharmaceuticals, INC | $82.18 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $31.34 | 2023 | Sutab, Suflave |
| Ferring Pharmaceuticals INC. | $30.18 | 2023 | Rebyota |
| Redhill Biopharma INC. | $23.40 | 2021 | |
| Boston Scientific Corporation | $20.69 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $20.58 | 2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $18.29 | 2024 | |
| Alnylam Pharmaceuticals INC. | $17.12 | 2022 | |
| Novo Nordisk INC | $16.60 | 2025 | Wegovy, Saxenda |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $15.31 | 2019 | |
| Ardelyx, INC. | $14.83 | 2023 | Ibsrela |
| Shire North American Group INC | $13.63 | 2019 | |
| Alexion Pharmaceuticals, INC. | $12.54 | 2019 | |
| Allergan, INC. | $11.02 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$43,252.65 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Petro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.